Pearls to optimize safety, success with biologics One dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach. Top 5 of 2016: Pediatric dermatology December 05, 2016 This year has seen many advancements in pediatric dermatologic care spanning inflammatory conditions to skin cancer as well as the nuances of these conditions in skin of color patients. These are the top 5 pediatric articles of 2016 from Dermatology Times. Study offers new insight into pediatric eczema December 02, 2016 By Lisette Hilton Researchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease. Advances in pediatric inflammatory skin disease December 02, 2016 By Bob Kronemyer Exciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population. Phase 3 results demonstrate dupilumab efficacy December 01, 2016 By Lisette Hilton New data suggests positive safety and efficacy profile. Further studies need to assess long-term use. Infant’s disseminated rash is twice misdiagnosed A frustrated mother carries her 2-month-old son into the office for evaluation of a diffuse bright red rash with dramatic hypopigmentation. Scalp, neck, axillary, and diaper areas are involved. Knowledge of skin microbiome provides insights into dermatological conditions November 30, 2016 By Louise Gagnon Direct sequencing data, together with culture data, supplies researchers with information about communities of bacteria and fungi on the skin. Integrating pharmacy benefit, medical benefit cuts costs November 29, 2016 By Tracey Walker Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs. Study offers new insight into pediatric eczema November 14, 2016 By Lisette Hilton Researchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease. FDA approves etanercept for pediatric psoriasis November 08, 2016 By Bernard A Cohen MD The US Food and Drug Administration (FDA) approval of etanercept for treatment of children with moderate to severe plaque psoriasis will revolutionize the management of psoriasis in children.